FEATURES OF THE ORIGIN OF FATTY LIVER DYSTROPHY IN ADOLESCENTS
Keywords:
fatty hepatosis, body mass index, obesity, adolescents, clinical and metabolic risk factors.Abstract
In this article, the influence of clinical-metabolic risk factors on the development of fatty hepatosis and the role of this disease in the deepening of obesity in the conditions of simple (exogenous-constitutional) obesity in 93 adolescents aged 17-30 years were determined. According to the results of the study, it was determined that abdominal obesity, insulin resistance, and stress are the most sensitive risk factors for the development of fatty hepatosis in adolescents. However, high specific risk factors include atherogenic dyslipidemia, hypertriglyceridemia, insulin resistance, inflammatory and prothrombotic conditions, and microalbuminuria. The frequency of fatty hepatosis among teenagers was 22%. We found out that the causes of fatty hepatosis in this age group are lack of energy, poor nutrition, and high consumption of energy products. Thus, taking into account the individual risk factors of adolescents in the early stages of fatty hepatosis, it is recommended to include drugs with hypolipidemic and hepatoprotective properties in the complex therapy for the prevention of fatty hepatosis.
References
Borsukov AV, Kryukovskij SB, Pokusaeva VN, Nikiforovskaya EN, Peregudov IV, Morozova TGE lastography in clinical hepatology (special issues). Smolensk: Smolensk City Printing House, 2011.
Drapkina OM, Korneeva ON The spectrum of nonalcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016; 12(4):424-429.https://doi.org/10.20996/1819-6446-2016-12-4-424-429
Ivashkin VT, Bakulin IG, Bogomolov PO, Matsievich MV, Geyvandova NI [et al.] Results of a clinical study evaluating the efficacy and safety of a combination of glycyrrhizic acid and essential phospholipids (Fosfogliv) in nonalcoholic fatty liver disease. Rossijskij zhurnal gastroenterologii, hepatologii, coloproctologii. 2017;27(2):34-43. https://doi.org/10.22416/1382-4376-2017-27-2-34-43
Meex RCR, Watt MJ Hepatokines: the relationship between nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 2017; 13(9):509-520. https://doi.org/10.1038/ nrendo.2017.56
Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease and diagnostic accuracy of noninvasive tests for assessing liver disease severity. Ann. Med. 2011; 43:617-649. https://doi.org/10.3109/07853890.2010.518623
Guidelines for the management of nonalcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
Nolan PB, Carrick-Ranson G, Stinear JW, Reading SA, Dalleck LC Prevalence of metabolic syndrome and its components among young adults: a meta-analysis. Prev. Med. Rep. 2017; 7:211-215. https://doi.org/10.1016/j.pmedr.2017.07.004
Shirokova EN Nonalcoholic fatty liver disease, hyperlipidemia, and cardiovascular risks. Consilium Medicum. 2017; 19(8.2):74-76. https://doi.org/10.26442/2075-1753_19.8.2.74-76
Timakova A. Yu., Skirdenko Yu. P., Livzan MA, Krolevets TS, Nikolaev NA, Nelidova AV Cardiovascular disease associated with nonalcoholic fatty liver disease. Experimental and clinical gastroenterology. 2020;182(10):88-95. https://doi.org/10.31146/1682-8658-ecg-182-10-88-95
Vlasov NN, Kornienko EA Nonalcoholic fatty liver disease and metabolic syndrome in children. Experimental and Clinical Gastroenterology. 2020; 183(11):51-61. https://doi.org/10.31146 /1682-8658-ecg-183-11-51-61
